Navigation Links
InterMune to Present at 2010 Citi Health Care Conference
Date:5/21/2010

BRISBANE, Calif., May 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Steve Porter, M.D., Ph.D., Chief Medical Officer and Senior Vice President, Clinical Affairs of InterMune, will present at the 2010 Citi Health Care Conference in New York on May 26 at 3 p.m. EDT.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com.  The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.  InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections.  The pulmonology portfolio includes pirfenidone for which InterMune has completed a Phase 3 program in patients with IPF (CAPACITY).  A Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA).  The hepatology portfolio includes the HCV protease inhibitor compound danoprevir (also known as RG7227 or ITMN-191, partnered by Roche) that entered Phase 2b in August 2009 and a second-generation HCV protease inhibitor research program.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
2. InterMune to Release First Quarter Financial Results on April 29
3. InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
4. InterMune Announces Proposed Public Offering of Common Stock
5. InterMune to Release Third Quarter Financial Results on November 5
6. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
7. InterMune to Present at Canaccord Adams Conference
8. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
9. InterMune to Release Second Quarter Financial Results on August 6
10. InterMune to Present at Goldman Sachs Healthcare Conference
11. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... today announced the three Winners and six Finalists of the 2017 Blavatnik Regional ... by the Blavatnik Family Foundation and administered by the New York Academy of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... United States multicenter, prospective clinical study that demonstrates the accuracy of the ... of identifying clinically significant acute bacterial and viral respiratory tract infections by ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global contract ... to improve patient outcomes and quality of life, will now be offering its ... attributed to new regulatory requirements for all new drug products, including the finalization ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research ... Inc. has been selected for membership in ARCS Alumni Hall of Fame ...
Breaking Biology Technology:
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
(Date:4/11/2017)... PALM BEACH GARDENS, Fla. , April 11, ... biometric identity management and secure authentication solutions, today ... million contract by Intelligence Advanced Research Projects Activity ... technologies for IARPA,s Thor program. "Innovation ... the onset and IARPA,s Thor program will allow ...
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
Breaking Biology News(10 mins):